MIRA Pharmaceuticals, Inc. (MIRA)
(Delayed Data from NSDQ)
$1.85 USD
-0.02 (-1.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.70 +0.85 (45.95%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMMIRA Pharmaceuticals, Inc. (MIRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.75 | $16.50 | $11.00 | 635.29% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for MIRA Pharmaceuticals, Inc. comes to $13.75. The forecasts range from a low of $11.00 to a high of $16.50. The average price target represents an increase of 635.29% from the last closing price of $1.87.
Analyst Price Targets (2 )
Broker Rating
Only one brokerage firm provided a Buy-equivalent recommendation for MIRA Pharmaceuticals, Inc. This translates to an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to no recommendation a month ago.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | NA | NA | NA |
Buy | 1 | 1 | NA | NA | NA |
Hold | 0 | 0 | NA | NA | NA |
Sell | 0 | 0 | NA | NA | NA |
Strong Sell | 0 | 0 | NA | NA | NA |
ABR | 2.00 | 2.00 | NA | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | Ascendiant Capital Markets | Edward M Woo | Not Available | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 1 |
Average Target Price | $13.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.18 |